Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus | Zendy

Robert P. Giugliano | Zendy; Christopher P. Can | Zendy; Michael A. Blazing | Zendy; José Carlos Nicolau | Zendy; Ramón Corbalán | Zendy; Jindřich Špinar | Zendy; JeongGun Park | Zendy; Jennifer A. White | Zendy; Erin A. Bohula | Zendy; Eugene Braunwald | Zendy

Open Access

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus

Author(s) -

Robert P. Giugliano,

Christopher P. Can,

Michael A. Blazing,

José Carlos Nicolau,

Ramón Corbalán,

Jindřich Špinar,

JeongGun Park,

Jennifer A. White,

Erin A. Bohula,

Eugene Braunwald

Publication year - 2017

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.117.030950

Subject(s) - medicine , simvastatin , ezetimibe , hazard ratio , acute coronary syndrome , myocardial infarction , diabetes mellitus , cardiology , statin , placebo , clinical endpoint , confidence interval , proportional hazards model , randomized controlled trial , endocrinology , alternative medicine , pathology

Ezetimibe, when added to simvastatin, reduces cardiovascular events after acute coronary syndrome. We explored outcomes stratified by diabetes mellitus (DM).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research